Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Taiper** is an Italian prescription fixed-dose antibacterial product containing the extended-spectrum ureidopenicillin **piperacillin** and the beta-lactamase inhibitor **tazobactam**. Piperacillin covalently inhibits bacterial penicillin-binding proteins, disrupting peptidoglycan cross-linking and bacterial cell-wall synthesis; tazobactam inhibits susceptible beta-lactamases and protects piperacillin from enzymatic degradation. It is marketed by Errekappa Euroterapici as powder and solvent for intramuscular injection and as powder for intravenous infusion for serious susceptible bacterial infections, including severe pneumonia, complicated urinary tract infections, complicated intra-abdominal infections, complicated skin and soft-tissue infections, associated bacteremia, and febrile neutropenia. ([api.aifa.gov.it](https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/7091/farmaci/37667/stampati?ts=RCP))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperacillin + tazobactam (Errekappa Euroterapici).